DARVON W/ ASA
LOE Approachingaspirin; propoxyphene hydrochloride
NDAORALCAPSULEPriority Review
Approved
Nov 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Darvon w/ ASA is an oral capsule combining propoxyphene hydrochloride (a mild opioid analgesic) with aspirin (an NSAID) for pain relief. It was approved in 1957 and indicated for moderate pain management. The combination provides dual analgesic activity through opioid and anti-inflammatory mechanisms.
LOE Approaching
With LOE approaching and limited commercial data available, career opportunities are likely contracting and focused on transition planning and legacy product management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Darvon w/ ASA offers minimal career growth opportunities due to its LOE approaching status and zero linked job openings. Career progression would focus on legacy product management, regulatory maintenance, and transition planning rather than innovation or market expansion.
Brand ManagerProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.